Navigation Links
Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants
Date:11/6/2009

QUINCY, Mass., Nov. 6 /PRNewswire/ -- Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myriant's biobased Succinic Acid plants based on renewable feedstocks. The execution of this alliance marks an important milestone in Myriant's commercialization of biobased Succinic Acid and exemplifies Uhde's continued commitment to the renewable chemicals industry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20091021/NE96331LOGO )

Myriant, which has successfully piloted the Succinic Acid process previously together with Uhde, has begun production of ton-sized samples for its customers to verify commercial product specifications and quality. The company expects to begin commercial production of biobased Succinic Acid second half of 2010.

Under Myriant's build-own-operate strategy, the alliance agreement combines the full breadth of Uhde's design and process expertise with Myriant's leading renewable, biobased Succinic Acid technology for the rapid deployment of full-scale commercial facilities. Uhde Corporation of America will be Myriant's engineering contractor for projects located in the U.S.; Uhde GmbH will act as Myriant's EPC Contractor in all other regions of the world. "The addition of Uhde's capabilities and experience is a perfect complement to Myriant's Succinic Acid program," said Stephen Gatto, Myriant Chairman and Chief Executive Officer. "Utilizing Uhde's unsurpassed EPC track record represents the final piece of the puzzle in making the construction of world scale biobased Succinic Acid plants a reality."

With more than 2,000 plants to its credit, Uhde GmbH is one of the world's leading engineering companies in the design and construction of chemical, refining and other industrial plants. "Uhde GmbH has built up special expertise in the field of biotechnology since 2004, and we are very excited about matching that expertise with Myriant's leadership position in Succinic Acid," stated Dr. Joachim Schulze, Head of Uhde GmbH's BioTechnology Division.

Succinic Acid has been recognized by both government organizations and the chemical industry as one of the most promising biochemicals that can be produced from renewable feedstocks to replace a wide range of petroleum-based chemicals. Myriant's renewable Succinic Acid offers cost competitive performance, reduced price volatility and a significantly enhanced environmental footprint as compared to petroleum-based alternatives. Given Succinic Acid's versatility, it can be used in a wide range of applications including polymers, solvents, pharmaceuticals, food and pigments. Typical end products that can utilize renewable Succinic Acid include car components, computer and electronic casings, shoe soles and paints.

Uhde GmbH has a workforce of more than 4,900 employees worldwide and is a company in the Plant Technology business area of the ThyssenKrupp Group. The company's activities focus on the engineering and construction of chemical and other industrial plants in the following fields: fertilisers; electrolysis; gas technologies; oil, coal and residue gasification; refining technologies; organic intermediates, polymers and synthetic fibres; and also coke plant and high-pressure technologies. "We also provide our customers with professional services and comprehensive solutions in all areas of industrial plant operation. Details are available at www.uhde.eu"

With a world-renowned team of molecular biologists, engineers and chemists, Myriant utilizes proprietary technology to advance the development of low-cost cellulosic sugars for the sustainable commercialization of high-value specialty chemicals. The company's D(-) lactic acid started production at commercial scale in June 2008 for use in polylactic acid. Myriant is headquartered in Quincy, Massachusetts. Details are available at www.myriant.com.

    Contacts:
    Myriant - Samuel G. McConnell, Sr. VP, Corporate Development
    (617) 657-5207
    Uhde Corporation of America - Dr. Dennis Lippmann, Managing Director
    (412) 257-8277
    Uhde GmbH - Dr. Joachim Schulze, Head of BioTechnology Division
    +49 (3 41) 9 89-74612
       Dr. Detlef Markmann, Head of Corporate Communications
       +49 (2 31) 5 47-3813

SOURCE Myriant Technologies LLC


'/>"/>
SOURCE Myriant Technologies LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
2. BioEnergy International, LLC Announces Formation of Myriant Technologies LLC
3. BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results
4. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009
6. TOPAZ Technologies Announces SoBran Inc. as New Customer
7. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
8. China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China
9. Epeius Biotechnologies to Partner at BIO Investor Forum
10. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
11. OriGene Technologies Acquires Marligen Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... January 21, 2017 , ... ... to bring to market a pioneering medical device for the treatment of Age-Related ... engagement contract with Emergo, a global regulatory consultancy that helps companies like ours ...
(Date:1/21/2017)... Jan. 20, 2017 Bioptix, Inc. ... announced that on January 14, 2017 the Board of ... the Company will terminate certain employees associated with the ... The Company commenced terminations on January 16, 2017 and ... The Company may pay severance benefits in certain circumstances ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
Breaking Biology Technology:
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
(Date:12/12/2016)... 12, 2016  Researchers at Trinity College, Dublin, ... by combining the material with Silly Putty. The mixture ... detector able to sense pulse, blood pressure, respiration, ... The research team,s findings were ... here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):